I would very briefly say that if we want to actually secure investments in innovative activities in Canada in the health field, we need to start thinking very strategically about how we invest directly in innovative platforms and science. Think tanks on the left and right of the political spectrum in Canada have pointed out that we rely far too heavily on indirect incentives created by tax expenditure subsidies and by the presumable argument that if we pay more for medicines in Canada we'll get more R and D.
The fact is that if you really want to attract excellence in R and D, you have to invest in the capacity, and, in a sense, that will come, because building capacity will attract R and D. It does require that we be strategic. Canada has never been a major player in what you would call the “small molecule pharmaceutical sector”, the traditional drugs of the past, but we have been a major player in biotech and other parts of the emerging pharmaceutical paradigm. What Canada may need is a national strategy to leverage where we're already fairly good and to take us from being fairly good to excellent as a mechanism to attract private investment.